The top after-market NASDAQ Stock Market gainers are: Gen-Probe, Questcor Pharmaceuticals, Panera Bread, Transcept Pharmaceuticals, and F5 Networks. The top after-market NASDAQ Stock Market losers are: Amazon.com, Human Genome Sciences, Masimo, Broadcom, and Century Aluminum.

Gainers

Gen-Probe Inc. (GPRO) stock jumped 19.59 percent to $71.01 in the after-market trading.

Questcor Pharmaceuticals, Inc. (QCOR) stock climbed 13.36 percent to $37.75 in the after-market trading. Profit for the third quarter was $22.85 million or $0.35 per share, higher than last year's $11.52 million or $0.18 per share. Adjusted profit rose to $24.31 million from $0.37 per share from $12.19 million or $0.19 per share last year. Sales grew to $59.82 million from $31.27 million. Analysts had expected profit of $0.26 per share on revenue of $53.42 million. Questcor's lead product H.P. Acthar Gel shipment grew 54 percent to 2,910 vials as paid prescriptions soared 174 percent to 886 for the treatment of multiple sclerosis exacerbations. H.P. Acthar Gel is an injectable drug for the treatment of certain disorders including exacerbation's associated with multiple sclerosis, infantile spasms, and nephrotic syndrome.

Panera Bread Co. (PNRA) stock grew 9.60 percent to $127.58 in the after-market trading. Profit for the third quarter was $29 million or $0.97 per share, up from $23 million or $0.75 per share last year. Revenue grew 22 percent to $453.09 million. Analysts had expected profit of $0.94 per share on revenue of $446.97 million. For the fourth quarter, the company expects earnings of $1.39 to $1.41 per share, while Street predicts $1.37 per share.

For the fiscal 2011, the company increased its earnings guidance to range of $4.63 to $4.65 per share from previous forecast of $4.54 to $4.58 per share, while Street now predicts $4.58 per share. Further ahead for fiscal 2012, the company initiated its earnings forecast of $5.38 to $5.48 per share, while Street predicts $5.29 per share. The company's chief executive officer Bill Moreton said its earnings guidance falls within its long-term target range of 15 percent to 20 percent annual earnings growth.

Transcept Pharmaceuticals, Inc. (TSPT) stock grew 9.10 percent to $8.15 in the after-market trading.

F5 Networks, Inc. (FFIV) stock gained 7.87 percent to $95.85 in the after-market trading. Adjusted profit for the fourth quarter was $85.2 million or $1.06 per share, up from $63.9 million or $0.79 per share last year. Revenue grew 24 percent to $314.6 million. Analysts had expected profit of $0.98 per share on revenue of $308.51 million. The company's board of directors has authorized an additional $200 million for its common stock share repurchase program. This new authorization is incremental to the $166 million currently in the existing program which was initially authorized in October 2010.

Looking ahead into the first quarter, the company expects adjusted earnings of $0.99 to $1.01 per share and revenue of $315 million to $320 million, while Street predicts profit of $1.00 per share on revenue of $320.14 million. For the fiscal 2012, the company anticipates sequential revenue growth throughout the year and solid year-over-year growth, while Street predicts a year-over-year growth of 18.4 percent.

Losers

Amazon.com Inc. (AMZN) stock plunged 12.44 percent to $198.89 in the after-market trading. Profit for the third quarter was $63 million or $0.14 per share, down from $231 million or $0.51 per share last year. Sales grew 44 percent to $10.88 billion. Excluding the $371 million favorable impact from year-over-year changes in foreign exchange rates throughout the quarter, sales would have grown 39 percent. Analysts had expected profit of $0.24 per share on revenue of $10.93 billion.

Looking ahead into the fourth quarter, Amazon.com expects sales of $16.45 billion to $18.65 billion, while Street predicts $18.10 billion. The company expects fourth quarter operating results between a loss of $200 million and a profit of $250 million. The guidance includes about $200 million for stock-based compensation and amortization of intangible assets.

Human Genome Sciences Inc. (HGSI) stock fell 11.67 percent to $11.20 in the after-market trading. Loss for the third quarter widened to $88.4 million or $0.45 per share from $40.9 million or $0.22 per share last year. Revenue fell to $34 million from $50.8 million. Analysts had expected a loss of $0.39 per share on revenue of $37.3 million. For the fiscal 2011, the company still anticipates selling, general and administrative expense of $150 million to $170 million and research and development expense of $180 million to $220 million. The company lowered its 2011 cash and investments guidance to range of $440 million to $470 million from previous forecast of $550 million to $650 million.

Masimo Corp. (MASI) stock tumbled 6.29 percent to $20.99 in the after-market trading. Profit for the third quarter was $14.8 million or $0.24 per share, down from $16.4 million or $0.27 per share last year. Revenue rose 3 percent to $104.04 million. Analysts had expected profit of $0.27 per share on revenue of $109.67 million.

For the fiscal 2011, the company lowered its earnings guidance to range of $1.04 to $1.06 per share from previous forecast of $1.17 to $1.25 per share. The company also reduced its 2011 revenue outlook to range of $436 million to $439 million from previous range of $446 million to $463 million. Street analysts currently predict profit of $1.16 per share on revenue of $449.49 million for the fiscal 2011.

Broadcom Corp. (BRCM) stock slid 4.94 percent to $34.03 in the after-market trading. Profit for the third quarter was $270 million or $0.48 per share, down from $328 million or $0.60 per share last year. Adjusted profit was $476 million or $0.82 per share, up from $456 million or $0.80 per share last year. Revenue grew 8.4 percent to $1.957 billion. Analysts had expected profit of $0.76 per share on revenue of $1.95 billion. for the fourth quarter, the company expects revenue fo $1.7 billion to $1.8 billion, while Street predicts $2.01 billion. The company expects fourth-quarter gross margin to be flat to down slightly versus last quarter.

Century Aluminum Co. (CENX) stock declined 4.03 percent to $9.76 in the after-market trading. Loss for the third quarter narrowed to $6.6 million or $0.07 per share from $16.8 million or $0.18 per share last year. The latest quarter results were negatively impacted by a mark-to-market loss on forward contracts of $12.1 million related primarily to aluminum put options. Sales rose to $345.6 million from $279.2 million. Analysts had expected profit of $0.15 per share on revenue of $352.50 million. Shipments of primary aluminum rose to 150,832 tonnes from 147,216 tonnes last year.

NASDAQ Stock Market